JP2022527276A5 - - Google Patents
Info
- Publication number
- JP2022527276A5 JP2022527276A5 JP2021557369A JP2021557369A JP2022527276A5 JP 2022527276 A5 JP2022527276 A5 JP 2022527276A5 JP 2021557369 A JP2021557369 A JP 2021557369A JP 2021557369 A JP2021557369 A JP 2021557369A JP 2022527276 A5 JP2022527276 A5 JP 2022527276A5
- Authority
- JP
- Japan
- Prior art keywords
- composition according
- unit dose
- peptide
- salt
- administered
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962824017P | 2019-03-26 | 2019-03-26 | |
| US62/824,017 | 2019-03-26 | ||
| PCT/US2020/024972 WO2020198481A1 (en) | 2019-03-26 | 2020-03-26 | Compositions and methods for treating ocular disease |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022527276A JP2022527276A (ja) | 2022-06-01 |
| JP2022527276A5 true JP2022527276A5 (https=) | 2023-03-28 |
| JP7650074B2 JP7650074B2 (ja) | 2025-03-24 |
Family
ID=72609544
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021557369A Active JP7650074B2 (ja) | 2019-03-26 | 2020-03-26 | 眼疾患を治療するための組成物及び方法 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US12540171B2 (https=) |
| EP (1) | EP3946418A4 (https=) |
| JP (1) | JP7650074B2 (https=) |
| KR (1) | KR20210146352A (https=) |
| CN (1) | CN113710264A (https=) |
| AU (1) | AU2020248438A1 (https=) |
| CA (1) | CA3134816A1 (https=) |
| EA (1) | EA202192607A1 (https=) |
| IL (1) | IL286625A (https=) |
| MX (1) | MX2021011727A (https=) |
| WO (1) | WO2020198481A1 (https=) |
| ZA (1) | ZA202107235B (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3886946A1 (en) | 2019-06-05 | 2021-10-06 | Regeneron Pharmaceuticals, Inc. | Devices and methods for precision dose delivery |
| CN117126233A (zh) * | 2022-05-20 | 2023-11-28 | 杭州禾泰健宇生物科技有限公司 | 一种类肽化合物及其应用 |
| USD1120314S1 (en) | 2022-11-30 | 2026-03-24 | Regeneron Pharmaceuticals, Inc. | Dose delivery device |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2015781A4 (en) * | 2005-09-12 | 2009-12-23 | Univ Johns Hopkins | COMPOSITIONS HAVING ANTIANGIOGENIC ACTIVITY AND USES THEREOF |
| EP2649095B1 (en) * | 2010-12-10 | 2021-10-06 | Aleksander S. Popel | Mimetic peptides derived from collagen type iv and their use for treating angiogenesis- and lymphangiogenesis- dependent diseases |
| JP6470740B2 (ja) * | 2013-06-07 | 2019-02-13 | ザ ジョンズ ホプキンス ユニバーシティ | 血管新生およびリンパ管新生依存性疾患の処置のための生体模倣ペプチドおよび生分解性送達プラットフォーム |
| CN108883150A (zh) | 2015-11-19 | 2018-11-23 | 阿斯克雷佩西治疗公司 | 具有抗血管生成、抗淋巴管生成以及消水肿性质的肽和纳米粒子制剂 |
| MX2019003895A (es) * | 2016-10-04 | 2019-10-07 | Asclepix Therapeutics Inc | Compuestos y metodos para activar la señalizacion tie2. |
| US20200179285A1 (en) * | 2017-05-08 | 2020-06-11 | The Johns Hopkins University | Biodegradable microparticles for sustained delivery of anti-angiogenic peptide |
| EP3661536A4 (en) * | 2017-08-03 | 2021-07-21 | Asclepix Therapeutics, Inc. | PROCESS FOR IDENTIFICATION AND MANUFACTURING OF PHARMACEUTICAL INGREDIENTS FOR ACTIVATING A TIE2 RECEPTOR |
-
2020
- 2020-03-26 CN CN202080030026.4A patent/CN113710264A/zh active Pending
- 2020-03-26 KR KR1020217034683A patent/KR20210146352A/ko active Pending
- 2020-03-26 EP EP20776493.7A patent/EP3946418A4/en active Pending
- 2020-03-26 US US17/442,682 patent/US12540171B2/en active Active
- 2020-03-26 WO PCT/US2020/024972 patent/WO2020198481A1/en not_active Ceased
- 2020-03-26 AU AU2020248438A patent/AU2020248438A1/en active Pending
- 2020-03-26 JP JP2021557369A patent/JP7650074B2/ja active Active
- 2020-03-26 EA EA202192607A patent/EA202192607A1/ru unknown
- 2020-03-26 MX MX2021011727A patent/MX2021011727A/es unknown
- 2020-03-26 CA CA3134816A patent/CA3134816A1/en active Pending
-
2021
- 2021-09-23 IL IL286625A patent/IL286625A/en unknown
- 2021-09-27 ZA ZA2021/07235A patent/ZA202107235B/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6438599B2 (ja) | 抗ｃｇｒｐ抗体製剤 | |
| US9044436B2 (en) | Compositions and methods for the treatment of angiogenesis-related eye diseases | |
| JP2022527276A5 (https=) | ||
| JP6738376B2 (ja) | 低減された投与容量を必要とする患者におけるベンダムスチン応答性症状の治療方法 | |
| JP2023541056A5 (https=) | ||
| KR101795643B1 (ko) | 전립선암 치료용 조성물 | |
| JP2025118607A5 (https=) | ||
| JP2019535651A5 (https=) | ||
| WO2017031319A1 (en) | Noradrenergic drug treatment of obstructive sleep apnea | |
| JP2021522180A5 (https=) | ||
| JP2023535744A5 (https=) | ||
| JP2022502432A5 (https=) | ||
| CN107530334A (zh) | 可注射贮库制剂 | |
| JP2006513217A (ja) | 眼内用途のためのステロイド組成物 | |
| JP2022062153A (ja) | デュラグルチドを使用する方法およびデュラグルチドを含有する組成物 | |
| JP7650074B2 (ja) | 眼疾患を治療するための組成物及び方法 | |
| EP1320378A2 (en) | Improved protocol for paracentesis | |
| BR112019026336A2 (pt) | forma de sal de cloridrato de um peptídeo análogo da porção c-terminal de c5a e o uso da mesma, composição, método para induzir uma resposta imune contra uma infecção ou câncer, kit e composto para aumentar uma resposta imune para um agente imunogênico | |
| CN102440957B (zh) | 醋酸特利加压素鼻腔喷雾剂及其制备方法 | |
| TW201440783A (zh) | 含有米卡芬淨或其鹽的醫藥組成物 | |
| WO2014059363A1 (en) | Oral solution formulations of aripiprazole | |
| CN114096269B (zh) | 高浓度胰岛素制剂 | |
| CN102504018A (zh) | 可持续释放的蜂毒肽帕莫酸盐及其制剂 | |
| CN104958762A (zh) | 一种33g针头注射用雷珠单抗眼玻璃体腔内缓释药物 | |
| WO2026013454A1 (en) | Multi-dose pen of tirzepatide |